The latest Tweets from Hartaj Singh (@hartajsingh). “ Or the exquisite delicate thin curve of the new moon in spring; ” W. Whitman, Miracles. New York. Hartaj Singh works at Oppenheimer. Before joining Oppenheimer, he was the director/biotechnology analyst for BTIG and a portfolio manager for Tecumseh. Hartaj Singh is Managing Director and Senior Analyst covering Biotechnology. Prior to joining Oppenheimer, Hartaj was Managing Director and Senior.
|Published (Last):||18 October 2009|
|PDF File Size:||3.29 Mb|
|ePub File Size:||4.26 Mb|
|Price:||Free* [*Free Regsitration Required]|
Jason began his career in equity research at Schroder Wertheim.
Oppenheimer Analyst Bios
Andrew Uerkwitz Emerging Services and Technology. Prior to Oppenheimer, Tim worked on the buy-side in an investment capacity at BlackRock. Prior to joining the firm, John was Senior Market Strategist at Ticonderoga Securities where he provided all macro, market outlook, and strategy ideas to the firm and its clients. Leah returns to the firm after an extremely productive period covering biotechnology on both the sell and buyside.
Growth in company valuations has outpaced sales for several years, but the coming weeks will see rapid fluctuations as the two begin to realign. In this interview, Singh shares his predictions for the rest of with The Life Sciences Reportand identifies several companies to hold for potentially big returns.
He also holds an M. His research methodology is based on proprietary survey-driven micro research on covered companies and framed by in depth macro research on the technology sector. Brian graduated from Creighton University with a B. Please see Overview for more details. Hartaj has a B. The following articles are merged in Scholar. John Parks is Managing Director and Director of Research and oversees Oppenheimer’s overall research strategy and product. Erica joined the firm in as an associate analyst in the Travel and Leisure space and subsequently covered e-Commerce companies before moving into her current position.
Prior to joining Oppenheimer, she was part of the Major and Specialty Pharmaceuticals equities research team at Deutsche Bank, where she launched as lead analyst on small and mid-cap companies.
Prior to Wall Street, Jay spent 18 years in the pharmaceutical industry, working mostly for Pfizer in finance, marketing and business development. He has been a CFA charterholder since Erica Moffett is Managing Director and Associate Director of Research and works with John Parks in overseeing the firm’s overall research strategy and product.
Inhe ranked in the top five for his orthopedics coverage in the Greenwich analyst survey. A from Boston University. Subscribe to Streetwise Reports. Leland also has both sell-side and buy-side experience and began his career on Cowen’s biotechnology research team, where he provided sole coverage focused in the small and mid-cap segment.
Email address for updates. He initially focused on the emerging Israeli technology companies before broadening his coverage to Emerging Technology and Service companies. While at ClinTrials Research, he coordinated clinical management for an anti-epileptic new drug application NDAand was the youngest clinical project manager to lead an NDA filing.
His coverage focuses on managed care, hospitals, nursing homes, home health, hospice, emergency services, and related healthcare services. He also is a Chartered Financial Analyst and was a C.
Hartaj Singh | The University of Manchester –
Tim researches a broad range of communications and cloud companies with a focus on emerging services and applications. He also is a CFA charterholder. She holds a B. Natural history of congenital kyphosis and kyphoscoliosis: Prior to joining the firm, he worked as a financial analyst and market researcher for Eurofon, Inc.
Patent and Trademark Office.
singn Clients value the market and stock specific insights of Brian and leverage his strong relationships with senior managements.
New articles related to this author’s research. She began her career at SAC Capital in equity and fixed income financing trading. She has been with the firm sinceoriginally working on the banks and brokers team alongside Chris Kotowski. My profile My library Hartam Alerts. Brian has worked as a sell side equity research analyst covering various areas of the retail and consumer economies for more than 20 years.
He served for five years in the Special Forces of the Israeli Defense Forces, where he held the rank of lieutenant. Prior to joining Oppenheimer, Andrew worked in equity research at Ardour Capital and also in investment banking at Deutsche Bank.
Expert – Hartaj Singh
A in Finance from the F. His tenure at Navigant Consulting enabled him to conduct hundreds of interviews with company executives and physicians, enhancing his understanding of their specific challenges. Prevalence of substance abuse in schizophrenia: